



Citi Pharma Limited

03rd March 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Subject: Material Information


Dear Sir,

In accordance with the Section 96 of Securities Act 2015 and Clause 5.6.1 (a) of Code of Corporate Governance contained in the PSX Rule Book, we hereby convey the following material information:

The Board of Directors of Citi Pharma Limited has approved the initiation of the Initial Public Offering of Citi Pharma's wholly owned subsidiary, Citi Veterinary Pharma Limited. The Company has been established as a dedicated entity focused towards the manufacturing of Veterinary focused API's and Pharmaceutical products for the consumption of the local market.

In this regard, the Board has approved the appointment of **K-Trade Securities Limited as the Consultant to Issue** with the aim to list the Company at the earliest. **The Company plans to raise between PKR 1.0 billion to PKR 2.0 billion** through the IPO.

This marks a significant milestone for Citi Pharma Limited for increasing it's revenue sources through diversification in a pharma related field. It may also be informed that **Citi Pharma plans to generate approx. PKR 1.50 billion in revenue through trading of veterinary products in FY26.**




Company Secretary,
Citi Pharma Limited



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392  www.citipharma.com.pk